Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XF8W
|
|||
| Former ID |
DAP000660
|
|||
| Drug Name |
Pyrazinamide
|
|||
| Synonyms |
Aldinamid; Aldinamide; Braccopiral; Corsazinmid; Dipimide; Eprazin; Farmizina; Isopas; Lynamide; Novamid; Pezetamid; Pharozinamide; Piraldina; Pirazimida; Pirazinamid; Pirazinamida; Pirazinamide; Prazina; Pyrafat; Pyramide; Pyrazide; Pyrazinamdie; Pyrazinamidum; Pyrazineamide; Pyrazinecarboxamide; Rozide; Tebrazid; Tebrazio; Tisamid; Unipyranamide; Zinamide; Zinastat; P ezetamid; Pirazinamide [DCIT]; Pyrazine carboxamide; Pyrazine carboxylamide; Pyrazinecarboxylic acid amide; Pyrazinoic acid am ide; Pyrazinoic acid amide; DRG 0124; MK 56; P 7136; Pyrazinamide BP 2000; T 165; AZT + Pyrazinamide combination; D-50; Pirazinamida [INN-Spanish]; Pms-Pyrazinamide; Pyrazinamide (TN); Pyrazinamidum [INN-Latin]; D-50 (VAN); Pyrazinamide [INN:BAN:JAN]; Pyrazine-2-carboxamide; Pyrazinamide (JP15/USP/INN); Pyrazinoic acid amide, Pezetamid, Pyrafat, Zinamide, Tebrazid, Pyrafat, Pyrazinamide; 2-Carbamylpyrazine; 2-carbamyl pyrazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Mycobacterium infection [ICD-11: 1B10-1B21] | Approved | [1], [2], [3] | |
| Therapeutic Class |
Antitubercular Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C5H5N3O
|
|||
| Canonical SMILES |
C1=CN=C(C=N1)C(=O)N
|
|||
| InChI |
1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)
|
|||
| InChIKey |
IPEHBUMCGVEMRF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 98-96-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3115, 5057, 78938, 602930, 866420, 3135875, 7437580, 7847212, 7980439, 8002616, 8139959, 8149510, 10321757, 10539072, 11111657, 11111658, 11335416, 11360655, 11363796, 11366358, 11368920, 11371892, 11374989, 11377082, 11461627, 11466542, 11467662, 11485105, 11486124, 11489121, 11490861, 11493000, 11494716, 15119868, 16957225, 17389747, 17405569, 24278648, 24439399, 24887930, 25623302, 26611902, 26679227, 26697102, 26747228, 26747229, 26752748, 39214717, 46507478, 47810638
|
|||
| ChEBI ID |
CHEBI:45285
|
|||
| ADReCS Drug ID | BADD_D01880 | |||
| SuperDrug ATC ID |
J04AK01
|
|||
| SuperDrug CAS ID |
cas=000098964
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Fatty acid synthetase I (Bact inhA) | Target Info | Inhibitor | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7287). | |||
| REF 2 | Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000 Sep;6(9):1043-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.